IDEXX Laboratories is a global leader in PET Healthcare innovation and recently announced a first-of-its-kind diagnostic panel with early detection of canine lymphoma. Dubbed IDEXX Cancer DX™, this innovation is important because studies show that 20 million dogs are at higher risk for cancer in North America, with one in four dogs expected to be diagnosed in their lifetime.
IDEXX Cancer DX™ is essentially “an affordable and accessible blood test that can be added to panels for sick pets and integrated into annual wellness screenings for as little as $15.” The diagnostic panel has great sensitivity and accuracy, while the service design has been streamlined to fit seamlessly into existing veterinary workflows. Results are delivered with IDEXX Medical Consultants—from board-certified oncologists to internists.
Image credit: IDEXX Laboratories
